Outcomes Following Isolated Limb Infusion for Melanoma. A 14-Year Experience
- 29 May 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 15 (11), 3003-3013
- https://doi.org/10.1245/s10434-008-9954-6
Abstract
Isolated limb infusion (ILI) is a minimally invasive technique for delivering regional chemotherapy in patients with advanced and metastatic melanoma confined to a limb. It is essentially a low-flow isolated limb perfusion (ILP) performed via percutaneous catheters without oxygenation. From our prospective database 185 patients with advanced metastatic melanoma of the limb treated with a single ILI between 1993 and 2007 were identified. In all patients a cytotoxic drug combination of melphalan and actinomycin-D was used. Drug circulation time was 20–30 min under mild hyperthermic conditions (38–39°C). The majority of patients (62%) were female. Their average age was 74 years (range 29–93 years). Most patients had MD Anderson stage III disease (134/185). The overall response rate was 84% [complete response (CR) rate 38%, partial response rate 46%]. Median response duration was 13 months (22 months for patients with CR; P = 0.01). Median follow-up was 20 months and median survival was 38 months. In those patients with a CR, the median survival was 53 months (P = 0.005). CR rate and survival time decreased with increasing stage of disease. On multivariate analysis significant factors for a favorable outcome were achievement of CR, stage of disease, thickness of primary melanoma, the CO2 level in the isolated circuit, and a Wieberdink limb toxicity score of III (considerable erythema and edema). The response rates and duration of response after ILI are comparable to those achieved by conventional ILP. ILI is a minimally invasive alternative to the much more complex and morbid conventional ILP technique for patients with advanced metastatic melanoma confined to a limb.Keywords
This publication has 39 references indexed in Scilit:
- Long-term Results of Hyperthermic, Isolated Limb Perfusion for MelanomaAnnals of Surgery, 2007
- Isolated limb perfusion for melanoma patients—a review of its indications and the role of tumour necrosis factor-αEuropean Journal of Surgical Oncology, 2006
- One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit MetastasesAnnals of Surgery, 2004
- Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanomaEuropean Journal of Surgical Oncology, 2004
- Isolated Limb Perfusion in the Management of Patients With Recurrent Limb Melanoma: An Important but Limited RoleAnnals of Surgical Oncology, 2001
- Thirty-five years of isolated limb perfusion for melanoma: Indications and resultsBritish Journal of Surgery, 1996
- A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremitiesEuropean Journal of Cancer, 1995
- Regional therapy of melanomaEuropean Journal of Cancer, 1993
- Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limbEuropean Journal of Cancer, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958